Accession Number : ADA259375


Title :   Combination Immunotherapy In Experimental Pseudomonas Sepsis


Corporate Author : WALTER REED ARMY INST OF RESEARCH WASHINGTON DC


Personal Author(s) : Cross, A S ; Opal, S M ; Palardy, J E ; Bodmer, M W ; Sadoff, J C


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/a259375.pdf


Report Date : Jan 1993


Pagination or Media Count : 8


Abstract : Immunotherapy has been shown to be effective adjuvant in the management of septic shock. A neuropenic rat model of septic shock induced by infection with pseudomonas aeruginosa 12.4.4 was used to determine the relative efficacy of single, double, and triple combination immunotherapy. A Pseudomonas 0 serotype-specific, opsonophagocytic monoclonal antibody, polyclonal J5 antiserum and a Mab directed against tumor necrosis factor (TNF) were studied as single therapy and in combination of all three immunotherapeutic agents resulted in a 77% survival rate. This level of of protection was superior to that achieved with any combination of two antibody treatments or single antibody therapy or compared with the control group. Immunotherapy directed against multiple steps of the septic process is more active than single or double antibody regimens and may offer an improved approach to the adjunctive treatment of septic shock.... Sepsis, Immunotherapy, Pseudomonas infection, Tumor necrosis factor, LPS Core glycolipid.


Descriptors :   *SEPSIS , *PSEUDOMONAS AERUGINOSA , CORES , MANAGEMENT , MODELS , RATS , RATES , NEOPLASMS , SHOCK , GLYCOLIPIDS , PSEUDOMONAS , PROTECTION , THERAPY , ANTIBODIES , IMMUNE SERUMS , MONOCLONAL ANTIBODIES , INFECTIOUS DISEASES , NECROSIS


Subject Categories : Medicine and Medical Research


Distribution Statement : APPROVED FOR PUBLIC RELEASE